Arkolith/Insider Trading/LGND/Form 4

Kozarich John W

DirectorLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed May 14, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$563K
Net Open-Market Flow
-$563K
Transactions
11
9 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 13, 2026Option exercise(M)2K$69.51$109K43K
May 13, 2026Sell(S)2K$223.50$352K42K
May 12, 2026Option exercise(M)459$69.51$32K42K
May 12, 2026Sell(S)459$224.00$103K42K
May 1, 2026Sell(S)116$234.09$27K42K
May 1, 2026Sell(S)80$227.37$18K42K
May 1, 2026Sell(S)1$229.87$23042K
May 1, 2026Sell(S)165$231.87$38K42K
May 1, 2026Sell(S)105$232.57$24K42K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 13, 2026Option exercise(M)2K—$00
May 12, 2026Option exercise(M)459—$02K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000049) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML